Table 2.
Baseline Mean ± SEM for All mRNAs Relative to TF2B
Controls (n=23; 19 F) | CFS Patients (n=22; 19F) | MS Patients (n=20; 18F) | P1 | η2 | |
---|---|---|---|---|---|
Metabolite Detecting | |||||
ASIC3 | 9.54E-03 ± 8.94E-04 | 8.26E-03 ± 1.19E-03 | 9.46E-03 ± 8.27E-04 | 0.59 | .01 |
P2X4 | 1.99E-01 ± 1.84E-02 | 1.97E-01 ± 2.08E-02 | 1.70E-01 ± 1.08E-02 | 0.45 | .03 |
P2X5 | 2.85E-01 ± 3.48E-02 | 2.68E-01 ± 3.07E-02 | 3.06E-01 ± 3.75E-02 | 0.74 | .02 |
TRPV1 | 1.42E-02 ± 1.52E-03 | 1.28E-02 ± 1.41E-03 | 1.36E-02 ± 7.28E-04 | 0.74 | .01 |
Adrenergic | |||||
α-2a | 3.51E-03 ± 3.82E-04 | 3.11E-03 ± 5.28E-04 | 6.47E-03 ± 1.68E-03* | 0.04 | .12 |
β-1 | 9.22E-03 ± 2.47E-03 | 2.31E-02 ± 1.17E-02 | 8.96E-03 ± 2.70E-03 | 0.30 | .04 |
β-2 | 1.15E+00 ± 1.79E-01 | 8.85E-01 ± 7.92E-02 | 8.99E-01 ± 6.43E-02 | 0.22 | .04 |
COMT | 1.89E-01 ± 1.36E-02 | 1.86E-01 ± 2.34E-02 | 2.19E-01 ± 2.05E-02 | 0.44 | .04 |
Immune | |||||
IL-6 | 5.58E-03 ± 2.55E-03 | 4.28E-03 ± 6.33E-04 | 4.98E-03 ± 9.28E-04 | 0.85 | .01 |
IL-10 | 4.90E-03 ± 6.14E-04 | 3.56E-02 ± 2.84E-02 | 5.77E-03 ± 6.60E-04 | 0.34 | .03 |
Lymphotoxin-α | 9.51E-02 ± 1.47E-02 | 9.62E-02 ± 2.31E-02 | 1.54E-01 ± 3.59E-02 | 0.20 | .05 |
TLR4 | 4.84E-01 ± 1.27E-01 | 4.94E-01 ± 6.62E-02 | 3.98E-01 ± 5.59E-02 | 0.72 | .01 |
CD14 | 1.74E+00 ± 1.46E-01 | 2.23E+00 ± 2.91E-01 | 2.09E+00 ± 2.32E-01 | 0.30 | .04 |
Table values are mRNA counts relative to control gene TF2B (mean ± SE)
p values calculated using oneway ANOVA
p<.05 vs controls, using post hoc Dunnett test